251 related articles for article (PubMed ID: 21667032)
21. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Nagy A; Schally AV; Emons G
Breast Cancer Res Treat; 2004 Oct; 87(3):255-64. PubMed ID: 15528968
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
23. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
25. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
27. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
28. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109
[TBL] [Abstract][Full Text] [Related]
29. [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.
Aggarwal S; Ndinguri MW; Solipuram R; Wakamatsu N; Hammer RP; Ingram D; Hansel W
Int J Cancer; 2011 Oct; 129(7):1611-23. PubMed ID: 21484797
[TBL] [Abstract][Full Text] [Related]
30. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
Emons G; Kaufmann M; Gorchev G; Tsekova V; Gründker C; Günthert AR; Hanker LC; Velikova M; Sindermann H; Engel J; Schally AV
Gynecol Oncol; 2010 Dec; 119(3):457-61. PubMed ID: 20828803
[TBL] [Abstract][Full Text] [Related]
31. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
32. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
Günthert AR; Gründker C; Böttcher B; Emons G
Anticancer Res; 2004; 24(3a):1727-32. PubMed ID: 15274347
[TBL] [Abstract][Full Text] [Related]
33. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
Jaszberenyi M; Schally AV; Block NL; Nadji M; Vidaurre I; Szalontay L; Rick FG
Oncotarget; 2013 Mar; 4(3):422-32. PubMed ID: 23518876
[TBL] [Abstract][Full Text] [Related]
35. [Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues].
Gaiser T; Rüschoff J; Schally AV; Keller G; Engel JB
Verh Dtsch Ges Pathol; 2006; 90():186-92. PubMed ID: 17867596
[TBL] [Abstract][Full Text] [Related]
36. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
[TBL] [Abstract][Full Text] [Related]
37. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
39. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
[TBL] [Abstract][Full Text] [Related]
40. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
